CD28H/IGPR-1 hFc Chimera, Human
CD28H/IGPR-1 HFc Chimera, Human

Immobilized Human B7-H7, His Tag at 5 μg/ml (100 μL/well) on the plate. Dose response curve for CD28H/IGPR-1 hFc Chimera, Human, hFc Tag with the EC50 of 63.4 ng/ml determined by ELISA.

CD28H/IGPR-1 HFc Chimera, Human

The purity of CD28H/IGPR-1 hFc Chimera, Human is greater than 95% as determined by SEC-HPLC.

CD28H/IGPR-1 HFc Chimera, Human

CD28H/IGPR-1 hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

CD28H/IGPR-1 HFc Chimera, Human

CD28H/IGPR-1 hFc Chimera, Human, His Tag captured on CM5 Chip via anti-his antibody can bind Human CD28H, hFc Tag with an affinity constant of 7.86 nM as determined in SPR assay (Biacore T200).

CD28H/IGPR-1 hFc Chimera, Human

CD28H is constitutively expressed on all naive T cells. Repetitive antigenic exposure, however, induces a complete loss of CD28H on many T cells, and CD28H negative T cells have a phenotype of terminal differentiation and senescence. After extensive screening in a receptor array, a B7-like molecule, B7 homologue 5 (B7-H5), was identified as a specific ligand for CD28H.
Z04184
¥72,752.00

Ask us a question
Product Introduction
Species Human
Protein Construction
CD28H/IGPR-1 (Leu23-Gly150)
Accession # Q96BF3-1
hFc
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE
> 95% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Immobilized Human B7­H7, His Tag at 5μg/ml (100μl/well) on the plate can bind CD28H/IGPR-1 hFc Chimera, Human. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 40.7 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 50-60 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Examples
  • CD28H/IGPR-1 HFc Chimera, Human
  • CD28H/IGPR-1 HFc Chimera, Human

    Immobilized Human B7-H7, His Tag at 5 μg/ml (100 μL/well) on the plate. Dose response curve for CD28H/IGPR-1 hFc Chimera, Human, hFc Tag with the EC50 of 63.4 ng/ml determined by ELISA.

  • CD28H/IGPR-1 HFc Chimera, Human
  • CD28H/IGPR-1 HFc Chimera, Human

    The purity of CD28H/IGPR-1 hFc Chimera, Human is greater than 95% as determined by SEC-HPLC.

  • CD28H/IGPR-1 HFc Chimera, Human
  • CD28H/IGPR-1 HFc Chimera, Human

    CD28H/IGPR-1 hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

  • CD28H/IGPR-1 HFc Chimera, Human
  • CD28H/IGPR-1 HFc Chimera, Human

    CD28H/IGPR-1 hFc Chimera, Human, His Tag captured on CM5 Chip via anti-his antibody can bind Human CD28H, hFc Tag with an affinity constant of 7.86 nM as determined in SPR assay (Biacore T200).


Background
Target Background CD28H is constitutively expressed on all naive T cells. Repetitive antigenic exposure, however, induces a complete loss of CD28H on many T cells, and CD28H negative T cells have a phenotype of terminal differentiation and senescence. After extensive screening in a receptor array, a B7-like molecule, B7 homologue 5 (B7-H5), was identified as a specific ligand for CD28H.
Synonyms TMIGD2; IGPR1; IGPR-1; CD28H; TPC1

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.